ADAR1 Capital Management LLC Buys New Position in Biogen Inc. $BIIB

Key Points

• ADAR1 Capital Management initiated a Biogen position by purchasing 17,900 shares worth approximately $3.87 million in the second quarter. Institutional investors collectively own about 87.93% of BIIB.
• Biogen reported stronger-than-expected quarterly results, with adjusted EPS of $3.60 and revenue of $2.74 billion, while revenue increased 3.4% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $227.79.
• LEQEMBI IQLIK, Biogen and Eisai’s once-weekly Alzheimer’s autoinjector, launched in the U.S., potentially improving treatment convenience and adoption. However, boxed-warning safety risks, MRI monitoring requirements and valuation concerns remain potential constraints.

ADAR1 Capital Management LLC purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 17,900 shares of the biotechnology company's stock, valued at approximately $3,867,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BIIB. Empowered Funds LLC increased its holdings in Biogen by 64.9% during the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company's stock worth $965,000 after purchasing an additional 2,777 shares during the last quarter. Focus Partners Wealth grew its holdings in Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company's stock worth $1,392,000 after acquiring an additional 6,436 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Biogen in the 2nd quarter worth about $216,000. Cerity Partners LLC raised its stake in shares of Biogen by 15.3% in the 2nd quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company's stock valued at $5,847,000 after purchasing an additional 6,184 shares in the last quarter. Finally, NewEdge Advisors LLC raised its stake in shares of Biogen by 13.4% in the 2nd quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company's stock valued at $336,000 after purchasing an additional 316 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: LEQEMBI IQLIK launches in the U.S.: Biogen and Eisai announced that the once-weekly subcutaneous autoinjector is now available to initiate treatment for adults with early Alzheimer’s disease. The option can be administered at home, potentially reducing clinic visits, improving treatment convenience and expanding adoption of LEQEMBI. LEQEMBI IQLIK Autoinjector Available in the U.S.
• Positive Sentiment: Potential commercial benefit: LEQEMBI IQLIK offers flexibility between intravenous and subcutaneous dosing for both initiation and maintenance therapy. Easier administration could lower barriers for patients and caregivers and support longer-term revenue growth from Biogen’s Alzheimer’s partnership with Eisai. The drug has demonstrated a 27% slowing of cognitive decline versus placebo in the pivotal study, although Biogen shares commercialization with Eisai.
• Positive Sentiment: Fundamental and institutional support: Biogen’s latest reported quarter included adjusted EPS of $3.60 and revenue of $2.74 billion, both ahead of expectations. Recent data also indicate more institutional investors increased positions than reduced them, while several analysts maintain Buy or Outperform ratings and a median price target around $225.
• Neutral Sentiment: Short-interest report appears unreliable: The data lists zero shares sold short both before and after the reporting period, making the stated “large increase” and NaN percentage mathematically meaningless. It provides no credible evidence of a short squeeze or materially changed investor positioning.
• Negative Sentiment: Bearish valuation commentary: A recent analysis titled “3 Reasons to Sell BIIB” argues that the shares’ roughly 14.4% six-month gain has largely followed the broader market, raising questions about additional upside and relative attractiveness. The article’s bearish view could limit enthusiasm after the recent rally. 3 Reasons to Sell BIIB and 1 Stock to Buy Instead
• Negative Sentiment: LEQEMBI safety risks remain: The treatment carries a boxed warning for amyloid-related imaging abnormalities, including potentially serious brain swelling and hemorrhage. These risks, along with required MRI monitoring and higher ARIA incidence among ApoE ε4 homozygotes, could constrain uptake and increase implementation costs.

Biogen Stock Up 1.2%

BIIB stock opened at $220.77 on Wednesday. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen Inc. has a fifty-two week low of $131.52 and a fifty-two week high of $222.85. The firm's 50-day simple moving average is $206.42 and its 200 day simple moving average is $195.12. The stock has a market cap of $32.62 billion, a PE ratio of 39.07, a price-to-earnings-growth ratio of 6.80 and a beta of 0.17.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.94 by $0.66. The firm had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. Biogen's revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, sell-side analysts predict that Biogen Inc. will post 12.39 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on BIIB shares. HSBC reiterated a "reduce" rating and issued a $157.00 price target on shares of Biogen in a research note on Monday, July 6th. Citigroup raised their price objective on Biogen from $200.00 to $215.00 and gave the stock a "neutral" rating in a research note on Monday, August 3rd. Jefferies Financial Group reaffirmed a "buy" rating on shares of Biogen in a report on Monday, July 13th. Needham & Company LLC increased their target price on shares of Biogen from $255.00 to $256.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Finally, Wolfe Research raised shares of Biogen from a "peer perform" rating to an "outperform" rating and set a $300.00 price target for the company in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Biogen currently has a consensus rating of "Moderate Buy" and an average target price of $227.79.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source